APAF-CRT: AV Junction Ablation and CRT in Permanent AF

Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) and heart failure (HF), sponsored by Centro Prevenzione Malattie Cardiovascolari Natalina e Vittorio Corbella. Primary endpoints: Combined end-point of HF mortality, HF hospitalization, AF hospitalization, or worsening HF at 3 years and Total mortality at 4 years. Status: unknown.